)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
LeMaitre Vascular
LeMaitre Vascular (LMAT) investor relations material
LeMaitre Vascular Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 net sales were $67.970M, up 11% reported and 12% organically; organic growth comprised 7% price and 5% unit growth.
Adjusted operating income and EPS each increased 5% YoY; FY 2026 guidance midpoint calls for 11% sales growth and 18% adjusted EPS growth.
9M sales rose 11% to $204.903M; net income was $47.753M versus $42.152M.
Financial highlights
Q3 operating income was $17.695M versus $20.312M; net income was $15.024M versus $17.362M.
Q3 gross margin was 71.7%, down 360 bps reported but up 90 bps excluding the $0.5M FAS-TIP inventory reserve; operating expenses rose 18% adjusted.
Diluted EPS was $0.65, down 14% reported and up 5% adjusted; adjusted EBITDA was $20.498M.
9M operating income was $55.869M versus $49.080M; gross profit was $147.9M, up 12%.
9M operating cash flow was $53.0M versus $58.1M; working capital used $12.9M, chiefly from prepaid expenses, inventory and receivables.
Outlook and guidance
FY 2026 sales guidance is $274.8M-$276.8M, midpoint $275.8M; organic growth 11%, gross margin 72.1%, operating income midpoint $75.4M and diluted EPS midpoint $2.80.
EPS guidance of $2.80 represents 18% growth from adjusted 2025; guidance includes a modest B. Braun acquisition impact.
Q4 sales guidance is $69.9M-$71.9M, midpoint $70.9M (+11% organic); gross margin 72.1%, operating income midpoint $19.5M and EPS midpoint $0.73.
Q4 guidance includes $150K of B. Braun product sales and break-even operating income impact; FY gross-margin guidance was reduced 30 bps from August, reflecting reserve, FX, fixed-cost leverage and RestoreFlow transfer timing.
Allograft tissue processing transfer from Fox River Grove to Burlington is expected to be substantially complete by year-end 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LeMaitre Vascular
- Q2 2026 saw double-digit sales and EPS growth, with strong margins and global expansion.LMAT
Q2 2026 - Q1 2026 saw 11% sales and 42% EPS growth, with raised guidance and strong biologics momentum.LMATQ1 2026
- Votes will be held on director elections, executive pay, and auditor ratification at the June 2026 meeting.LMATProxy filing
- Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.LMATProxy filing
- Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMATInvestor presentation
- Q4 2025 saw 16% sales and 47% profit growth; 2026 outlook features strong growth and capital returns.LMATQ4 2025
- Q3 2024 sales up 16%, EPS up 49%, with raised guidance and strong biologics-driven growth.LMATQ3 2024
- Q2 net income up 46% on 11% sales growth; 2024 guidance raised for sales and EPS.LMATQ2 2024
- Double-digit growth, margin gains, and higher shareholder returns drive 2025 outlook.LMATQ4 2024
Next LeMaitre Vascular earnings date
Q4 202625 Feb, 2027
LeMaitre Vascular
Next LeMaitre Vascular earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
LeMaitre Vascular Inc. is a medical device company that develops, manufactures, and markets products for the treatment of vascular diseases. The company's portfolio includes surgical implants, grafts, stents, and catheters used in procedures such as aneurysm repair, bypass surgery, and vessel closure. LeMaitre Vascular primarily serves vascular surgeons and hospitals, focusing on solutions that improve patient outcomes in peripheral vascular disease and other circulatory conditions. LeMaitre Vascular Inc. is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.